A5034744861- Epigenetics and DNA Methylation
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- RNA modifications and cancer
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- MicroRNA in disease regulation
- Cancer Treatment and Pharmacology
- Advanced Radiotherapy Techniques
- Neuroscience and Neural Engineering
- Histone Deacetylase Inhibitors Research
- Radiation Therapy and Dosimetry
- Advanced Breast Cancer Therapies
- Asthma and respiratory diseases
- Bacterial Identification and Susceptibility Testing
- Bone health and treatments
- Photoreceptor and optogenetics research
- Influenza Virus Research Studies
- Cancer Diagnosis and Treatment
- Medical Imaging Techniques and Applications
- Peptidase Inhibition and Analysis
- Sarcoma Diagnosis and Treatment
- Respiratory viral infections research
- Metabolism and Genetic Disorders
University of Washington
2023-2025
Tokuyama (Japan)
2024-2025
Fred Hutch Cancer Center
2024-2025
Chiba Cancer Center
1998-2021
Seattle University
2021
University of Chicago
2018-2020
National Cancer Centre Japan
2018
Kyoto University
2017-2018
Aichi Cancer Center
2009-2018
Sakai Municipal Hospital
2018
Aldehyde oxidase (AO; EC 1.2.3.1) that could oxidize indole-3-acetaldehyde into indole-3-acetic acid was purified approximately 2000-fold from coleoptiles of 3-d-old maize (Zea mays L.) seedlings. The apparent molecular mass the native enzyme about 300 kD as estimated by gel-filtration column chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed composed 150-kD subunits. It contained flavin adenine dinucleotide, iron, and molybdenum prosthetic groups had...
Intrahepatic cholangiocarcinoma (ICC) is an aggressive bile duct malignancy that frequently exhibits isocitrate dehydrogenase (
Dysregulated eIF4E-dependent translation is a central driver of tumorigenesis and therapy resistance. eIF4E binding proteins (4E-BP1/2/3) are major negative regulators that inactivated in tumors through inhibitory phosphorylation or downregulation. Previous studies have linked PP2A phosphatase(s) to activation 4E-BP1. Here, we leveraged biased small molecule activators (SMAPs) explore the role B56-PP2A(s) 4E-BP regulation potential B56-PP2A for restoring translational control tumors. SMAP...
<p>Supplementary Figure S4. CK5 and CK17 do not predict treatment response or time to recurrence. A) Combining GATA6 IHC does overall survival. B) high, low tumors display improved survival compared low, high tumors. C) Kaplan-Meier curves for positive negative treated with first-line gemcitabine chemotherapy. D) E) status F) show longer recurrence than tumors, the opposite phenotype expected from basal subtype.</p>
<p>Supplementary Figure S1. Example images of IHC FFPE samples. A) HMGA2 positive glands. B) GATA6 Scale bars = 50 μm.</p>
<p>Supplementary Figure S3. Consort Diagram and Mixed Populations. A) diagram of analyzed samples. For survival analyses, all patients with intact cores (n = 491) were assessed. treatment response further subdivided by type chemotherapy received, neoadjuvant-treated samples considered separately 51). B) (HMGA2+ GATA6+) double negative (HMGA2- GATA6-) populations show intermediate between basal classical tumors.</p>
<p>Supplementary Figure S6. GATA6 expression predicts chemotherapy response to GnP but not mFFX. A) GATA6low metastatic tumors have significantly worse overall survival when treated with combination first-line chemotherapy. B) status does predict patients receive first line mFFX chemotherapy.</p>
<div>AbstractPurpose:<p>The purpose of this study was to establish HMGA2 as a marker basal-like disease in pancreatic ductal adenocarcinoma (PDAC) and explore its use biomarker for prognosis treatment resistance.</p>Experimental Design:<p>We identified high-mobility group A2 (HMGA2) protein expression basal PDAC cells single-cell RNA sequencing (RNA-seq) atlas 172 patient samples. We then analyzed expression, along with the classic GATA-binding factor 6 (GATA6),...
<p>Supplementary Figure S5. Representative CD8+ and FAP+ scoring. CD8 (top) FAP (bottom) were scored on a scale of 0 (least staining) to 3 (most following the representative scale.</p>
<p>Supplementary Figure S2. Demographic data for analyzed cohort. A) Age distribution TMA and Ochsner cohorts. B) Race C) Proportions of disease by stage (left) resulting survival (right) predicts in cohort (AJCC 8th edition).</p>
<p>Supplementary Figure S6. GATA6 expression predicts chemotherapy response to GnP but not mFFX. A) GATA6low metastatic tumors have significantly worse overall survival when treated with combination first-line chemotherapy. B) status does predict patients receive first line mFFX chemotherapy.</p>
<p>Supplementary Figure S4. CK5 and CK17 do not predict treatment response or time to recurrence. A) Combining GATA6 IHC does overall survival. B) high, low tumors display improved survival compared low, high tumors. C) Kaplan-Meier curves for positive negative treated with first-line gemcitabine chemotherapy. D) E) status F) show longer recurrence than tumors, the opposite phenotype expected from basal subtype.</p>
<p>Supplementary Figure S2. Demographic data for analyzed cohort. A) Age distribution TMA and Ochsner cohorts. B) Race C) Proportions of disease by stage (left) resulting survival (right) predicts in cohort (AJCC 8th edition).</p>
<p>Supplementary Figure S5. Representative CD8+ and FAP+ scoring. CD8 (top) FAP (bottom) were scored on a scale of 0 (least staining) to 3 (most following the representative scale.</p>